ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,045.70
0.16%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immix Biopharma Inc (IMMX)

  7. Immix Biopharma Inc (IMMX) Noticias

IMMX

Immix Biopharma (IMMX)

Immix Biopharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMMX
FechaHoraFuenteTítuloSímboloCompañía
14/05/202420:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMMXImmix Biopharma Inc
09/05/202415:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMMXImmix Biopharma Inc
07/02/202416:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMMXImmix Biopharma Inc
06/02/202408:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMMXImmix Biopharma Inc
28/11/202309:48InvestorsHub NewsWireImmix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient DosingNASDAQ:IMMXImmix Biopharma Inc
09/11/202318:57Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMMXImmix Biopharma Inc
28/09/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMMXImmix Biopharma Inc
25/09/202315:15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMMXImmix Biopharma Inc
30/08/202315:15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:IMMXImmix Biopharma Inc
23/08/202315:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMMXImmix Biopharma Inc
25/07/202307:42GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual MeetingNASDAQ:IMMXImmix Biopharma Inc
17/07/202308:37GlobeNewswire Inc.Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
10/07/202308:47GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteNASDAQ:IMMXImmix Biopharma Inc
26/06/202308:49GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
22/06/202308:53GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
20/06/202308:45GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
16/06/202308:43GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
14/06/202306:30GlobeNewswire Inc.Immix Biopharma Completes $5 Million At-The-Market Equity Offering ProgramNASDAQ:IMMXImmix Biopharma Inc
13/06/202316:27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:IMMXImmix Biopharma Inc
12/06/202308:49GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
08/06/202305:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMMXImmix Biopharma Inc
26/05/202308:53GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing SiteNASDAQ:IMMXImmix Biopharma Inc
21/05/202315:05GlobeNewswire Inc.Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
21/05/202315:00GlobeNewswire Inc.Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
12/05/202316:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:IMMXImmix Biopharma Inc
04/05/202311:30GlobeNewswire Inc.Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)NASDAQ:IMMXImmix Biopharma Inc
03/05/202307:00GlobeNewswire Inc.Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody TislelizumabNASDAQ:IMMXImmix Biopharma Inc
26/04/202316:30GlobeNewswire Inc.Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in ParisNASDAQ:IMMXImmix Biopharma Inc
25/04/202315:53Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IMMXImmix Biopharma Inc
04/04/202307:00GlobeNewswire Inc.Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual MeetingNASDAQ:IMMXImmix Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:IMMX

Su Consulta Reciente

NASDAQ
AAZEYXX
Royal Bank of Canada Cap...
BMF
BITK24
BITK24 - Maio 2024
CSE
CMS
CDN MSolar
LSE
15AU
Municplty 48
USOTC
FALSF
Fireangel Safety Technol... (PK)
LQID
SNIPETH
BOV
BMKS3M
BIC MONARK ON
BOV
ESUT11F
Fip Ie III Ci A
TG
CCJ
Cincinnati Financial
USOTC
BWVI
Blue Water Ventures (PK)
EU
AFLBP
Agence France Locale Afl...
LSE
BNKS
Ish Sp Us Bnks
UNSW3
WHACKDETH
Whackd
BOV
BHYG39R
BlackRock Institutional ...
AQEU
GNC
GN Store Nord AS
ASX
FXYKOE
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados